IMV Inc. (IMVIF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.30: the stock has moved about 70% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerIMV Inc. (IMVIF) trades at $0.002. IMV Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapies. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for IMVIF: IMVIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IMVIF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
IMVIF: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
IMV Inc. (IMVIF) Healthcare & Pipeline Overview
IMV Inc. (IMVIF) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer and infectious diseases, leveraging its proprietary DPX platform to create targeted treatments for solid tumors and blood cancers.
What Is the Investment Thesis for IMVIF?
The company is advancing its lead candidate, maveropepimut-S, through critical Phase II trials, which could unlock significant market opportunities in the oncology space, particularly if successful in treating diffuse large B-cell lymphoma and ovarian cancer. Additionally, IMV's development of immunotherapies for infectious diseases like COVID-19 and RSV adds diversification to its portfolio. However, potential risks include the inherent uncertainties of clinical trial outcomes and the challenges of securing funding in a competitive landscape. The company's ability to navigate these challenges while advancing its clinical programs will be key to unlocking shareholder value.
Based on FMP financials and quantitative analysis
IMVIF Key Highlights
Market Cap: $0.00B, indicating a focus on clinical development with no current revenue.
- Beta: 0.30, suggesting lower volatility compared to the market.
- Employee count: 63, reflecting a lean operational structure.
- No dividend yield, emphasizing reinvestment in clinical trials and research.
- Focus on immuno-oncology, a rapidly growing sector within biotechnology.
Who Are IMVIF's Competitors?
IMVIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $63.34 | -0.64% | $129B | 905-pillar |
| NVS Novartis AG | $137.57 | +0.07% | $261B | 825-pillar |
| JAZZ Jazz Pharmaceuticals plc | $240.48 | -0.34% | $15.1B | 405-pillar |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are IMVIF's Key Strengths?
Innovative DPX platform enabling targeted immunotherapy development.
- Strong pipeline with multiple candidates in clinical trials.
- Experienced management team with expertise in biotechnology.
- Established presence in the immuno-oncology sector.
What Are IMVIF's Weaknesses?
Currently no revenue, relying on funding for operations.
- Clinical-stage status involves significant risks and uncertainties.
- Limited market presence compared to larger competitors.
- Potential challenges in securing additional funding.
What Could Drive IMVIF Stock Higher?
Results from Phase II clinical trials for maveropepimut-S expected in 2026.
- Development of DPX-SurMAGE in Phase I trials for bladder cancer.
- Initiation of Phase I trials for DPX-COVID-19 and DPX-RSV.
- Strategic partnerships to enhance research and development efforts.
- Potential announcements regarding funding or collaborations in 2026.
What Are the Key Risks for IMVIF?
Financial-distress signal — its Altman Z-Score of -11.97 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 7 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial outcomes remain uncertain and can impact stock performance.
- Regulatory challenges could delay product development timelines.
- Competition from established pharmaceutical companies in immuno-oncology.
- Market volatility affecting investor sentiment and funding availability.
What Are the Growth Opportunities for IMVIF?
- Expansion into Solid Tumor Markets: IMV Inc. is advancing maveropepimut-S through Phase II trials for various solid tumors, including ovarian cancer and bladder cancer. The solid tumor market is expected to grow significantly, with a projected CAGR of 8.5% through 2028, driven by increasing cancer incidence and a shift towards personalized medicine. Successful trial outcomes could position IMV to capture a share of this lucrative market.
- Development of DPX-SurMAGE: The ongoing Phase I evaluation of DPX-SurMAGE for bladder cancer represents a significant growth opportunity. If clinical trials demonstrate efficacy, IMV could establish itself as a key player in this therapeutic area, addressing unmet medical needs.
- Immunotherapy for Infectious Diseases: With the development of DPX-COVID-19 and DPX-RSV, IMV Inc. is tapping into the growing market for infectious disease therapies. The global market for infectious disease therapeutics is expected to reach $60 billion by 2027. This diversification not only mitigates risks associated with oncology but also positions IMV to benefit from increased demand for vaccines and therapies.
- Collaboration and Partnerships: IMV Inc. could explore strategic partnerships with larger pharmaceutical companies to enhance its research capabilities and expedite clinical trials. Collaborations can provide access to additional resources, funding, and expertise, potentially accelerating the development timeline for its therapies.
- Geographic Expansion: As IMV Inc. progresses through clinical trials, there may be opportunities to expand its market presence beyond North America into Europe and Asia. The global oncology market is expanding, and entering new regions could significantly increase the addressable market for IMV's therapies.
What Are IMVIF's Competitive Advantages?
- Proprietary DPX immune-modulating platform that enhances immune responses.
- Focused expertise in immuno-oncology, differentiating it from competitors.
- Innovative drug delivery technology that targets specific cancer cells.
- Strong pipeline of clinical candidates addressing unmet medical needs.
- Established reputation in the biotechnology community since 2000.
What Does IMVIF Do?
Founded in 2000, IMV Inc., originally known as Immunovaccine Inc., is a biopharmaceutical firm headquartered in Dartmouth, Canada. The company is dedicated to advancing immuno-oncology therapies through its proprietary DPX immune-modulating platform, which enables the development of a range of treatments targeting both solid tumors and hematological malignancies. IMV's flagship product, maveropepimut-S, is an immunotherapy designed to target cells expressing survivin, currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and various solid tumors, including those of the bladder and liver. Additionally, the company is investigating maveropepimut-S in Phase I trials for breast cancer. IMV's pipeline also includes DPX-SurMAGE, currently in Phase I evaluation for bladder cancer, as well as DPX-COVID-19 and DPX-RSV, which are aimed at addressing infectious diseases. The company has made significant strides since its inception, focusing on developing innovative therapies that leverage its unique drug delivery technology, which is designed to enhance immune responses against cancer cells. With a workforce of 63 employees, IMV Inc. is positioned to capitalize on the growing demand for advanced immunotherapies in the healthcare sector.
What Products and Services Does IMVIF Offer?
- Develop immunotherapies targeting cancer and infectious diseases.
- Utilize the proprietary DPX immune-modulating platform for drug delivery.
- Conduct clinical trials to evaluate the safety and efficacy of its therapies.
- Focus on solid tumors and blood cancers in its treatment pipeline.
- Engage in research collaborations to enhance therapeutic development.
- Seek regulatory approvals for its clinical-stage products.
How Does IMVIF Make Money?
- Generate revenue through the development and commercialization of innovative therapies.
- Engage in partnerships and collaborations with larger pharmaceutical companies.
- Leverage funding from grants and investors to support clinical trials and research.
- Potential future revenue from licensing agreements for its proprietary technologies.
- Focus on advancing clinical candidates to market for revenue generation.
What Industry Does IMVIF Operate In?
The biotechnology industry, particularly the immuno-oncology sector, is experiencing significant growth, driven by advancements in cancer therapies and increasing demand for personalized medicine. IMV Inc. operates in a competitive landscape that includes established players and emerging biotech firms, positioning itself with its proprietary DPX platform, which differentiates its product offerings through targeted immune modulation. As clinical results emerge, companies like IMV that focus on innovative therapies are likely to capture market share and attract investor interest.
Who Are IMVIF's Key Customers?
- Healthcare providers and hospitals seeking advanced cancer treatments.
- Patients diagnosed with solid tumors and blood cancers.
- Pharmaceutical companies interested in collaboration and licensing.
- Research institutions conducting studies in immuno-oncology.
- Investors and stakeholders in the biotechnology sector.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 42 |
| 2026-08-26 | 42 |
| 2026-08-29 | 42 |
| 2026-09-01 | 42 |
| 2026-09-04 | 42 |
| 2026-09-07 | 42 |
| 2026-09-10 | 42 |
What changed?
The score has stayed at 42.
Over the same 18 days the stock moved +0.0%.
Earnings Track Record
IMV Inc. has missed Wall Street's EPS estimate in 4 of its last 7 reported quarters — a mixed record worth weighing. Reported results have landed about 2.6% below estimates on average.
Financial Health
IMV Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.97 places it in the distress zone, a signal of elevated financial risk.
Company Profile
IMV Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dartmouth, CA. The company is led by CEO Andrew Hall. IMVIF has traded publicly since 2013.
Forward Outlook
Wall Street analysts project IMV Inc. revenue of about $21.8M for fiscal 2026, with EPS near $-2.68.
IMVIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative DPX platform enabling targeted immunotherapy development.
- Strong pipeline with multiple candidates in clinical trials.
- Experienced management team with expertise in biotechnology.
- Established presence in the immuno-oncology sector.
Bear Case
- Currently no revenue, relying on funding for operations.
- Clinical-stage status involves significant risks and uncertainties.
- Limited market presence compared to larger competitors.
- Potential challenges in securing additional funding.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
IMVIF Latest News
No recent news available for IMVIF.
IMVIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for IMVIF.
Price Targets
Wall Street price target analysis for IMVIF.
IMVIF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for IMVIF; grades run from A+ (80-100) to F (below 30).
Leadership: Andrew Hall
CEO
Andrew Hall has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on oncology and immunotherapy. Hall holds an MBA and has been instrumental in guiding IMV Inc. through its clinical development phases.
Track Record: Under Andrew Hall's leadership, IMV Inc. has advanced its clinical pipeline significantly, particularly with the progress of maveropepimut-S through multiple phases of clinical trials. His strategic vision has positioned the company to explore new therapeutic areas and expand its market reach.
IMVIF OTC Market Information
OTC Other tier stocks, like IMV Inc., are subject to less stringent reporting requirements compared to those listed on major exchanges like NYSE or NASDAQ. This can lead to lower liquidity and potentially higher volatility, as these companies may not be required to file regular financial reports or maintain the same level of transparency.
- OTC Tier: OTC Other
- Lower liquidity compared to stocks listed on major exchanges.
- Less stringent reporting and transparency requirements.
- Potential for higher volatility due to market dynamics.
- Increased risk of price manipulation in less regulated markets.
- Review recent clinical trial results and their implications.
- Assess the company's financial health and funding status.
- Evaluate the competitive landscape and market positioning.
- Monitor regulatory developments affecting the biotechnology sector.
- Investigate potential partnerships or collaborations.
- Established presence in the biotechnology sector since 2000.
- Ongoing clinical trials with potential for significant market impact.
- Experienced management team with a track record in drug development.
What Investors Ask About IMV Inc. (IMVIF) — Healthcare
Is IMVIF a good stock?
Stock Expert AI does not rate IMVIF buy, sell or hold. IMV Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for IMVIF?
The primary risks for IMV Inc. include uncertainties surrounding clinical trial outcomes, which could significantly affect the company's future. Regulatory challenges may also pose delays in product development.
What are the key factors to evaluate for IMVIF?
Evaluate IMVIF on fundamentals, analyst consensus, and risk factors. Market Cap: $0.00B, indicating a focus on clinical development with no current revenue. Not financial advice.
How frequently does IMVIF data refresh on this page?
IMVIF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven IMVIF's recent stock price performance?
IMV Inc. (IMVIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative DPX platform enabling targeted immunotherapy development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IMVIF overvalued or undervalued right now?
IMV Inc. (IMVIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of IMVIF?
Yes, most major brokerages offer fractional shares of IMV Inc. (IMVIF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track IMVIF's earnings and financial reports?
IMV Inc. (IMVIF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for IMVIF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial information may be limited due to OTC classification.